References
- Jun Y, Jimmy S, Peter JF. Diagnosing endocrine hypertension: a practical approach. Nephrol 2017;22(9):663–677.
- Isabella S, Felix B, Thomas FL. Secondary causes of hypertension. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW, editors. ESC CardioMed. 3rd ed. London: Oxford University Press; 2018;
- Reena MT, Ewa R, Prapimporn CS, Leonor C, Endocrine hypertension: An overview on the current etiopathogenesis and management options. World J Hypertens 2015;5(2):14–27.
- William FY, David AC, Jacques WML, Michael S, Stephen CT. Screening for endocrine hypertension: an endocrine society scientific statement. Endocr Rev 2017;38(2):103–22.
- Er LK, Wu VC. Call for screening for primary aldosteronism: an underdiagnosed and treatable disease, J Thorac Dis 2018;10(2):557–9.
- Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffallo F, et.al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69(14):1811–20.
- Born-Frontsberg E, Reincke M, Rump LC, Lorenz R, Hahner S, Diederich S. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metabol 2009;94(4):1125–30.
- Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et.al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2016;101(5):L1889–916.
- Zhou Y, Zhang M, Ke S, Liu L. Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. BMC Endocr Disord 2017;17(1):61.
- Kounatiadis P, Petroglou D, Kolettas V, Karvounis H, Primary aldosteronism of late onset: a case report. HIPPOKRATIA 2014;18(2):180–82.
- Yu R, Furmark L, Wong C, Cardiac abnormalities associated with pheochromocytoma and other adrenal tumors. Endocr Pract 2009;15(1):10–16.
- Tsirilin A, Oo Y, Sharma R, Kansara A, Gliwa A, Banerji MA, Pheochromocytoma: a review. Maturitas 2014;77(3):229–38.
- Guerrero MA, Schreinermakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg 2009;209(6):727.
- Kassim TA, Clarke DD, Mai VQ, et al. Catecholamine-induced cardiomyopathy. Endocr Pract 2008;14(9):1137–49.
- Chioncel V, Adam F, Sinescu I, Păun D, Sinescu C. Particularitățile clinice și paraclinice la pacienții hipertensivi cu feocromocitom – studiu retrospectiv. Rom J Cardiol 2012:22(2).
- Radojkovic D, Stojanovic M, Pesic M, Radojkovic M, Radenkovic S, et al. Clinically “silent” giant pheochromocytoma. case report. Acta Endocrinologica (BUC) 2013;9(1):121–29.
- Skov J, Sundstrom A, Ludvigsson JF, Kampe O, Bensing S. Sex-specific risk of cardiovascular disease in autoimmune addison disease – a population-based cohort study. J Clin Endocrinol Metab 2019;104(6):2031–40.
- Rahvar AH, Haas CS, Danneberg S, Harbeck B. Increased cardiovascular risk in patients with adrenal insufficiency: a short review. Biomed Res Int 2017;2017:3691913.
- Schumacher MM, Larsen TR, Sane DC. Cardiac manifestations of adrenal insufficiency. Rev Cardiovasc Med. 2016;17(3–4):131–36.
- Henry M, Kevin GFT, Ian LR, Sleep, cognition and cortisol in Addison's disease: a mechanistic relationship. Front Endocrinol (Lausanne) 2021;12:694046.